Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.

American journal of medical genetics - 8 Aug 2002

Mihara Kazuo, Kondo Tsuyoshi, Higuchi Hisashi, Takahashi Hitoshi, Yoshida Keizo, Shimizu Tetsuo, Kaneko Sunao

Abstract excerpt

Tardive dystonia is an uncommon but intractable and distressing complication of neuroleptic treatment. It is suggested that individual predisposing vulnerability plays a major role in the development of the side effect. This study aimed to investigate relationship tardive dystonia and several genetic factors such as polymorphism of cytochrome P4502D6, and receptor polymorphisms of dopamine D(2) (TaqI A and -141C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dystonia

Share to Gene Frequency

Share to Polymorphism, Genetic

Share to Receptors, Dopamine D2

Share to Receptors, Dopamine D3

Share to Schizophrenia

Source

Identifiers

PMID: 12210290
DOI: 10.1002/ajmg.10602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.PMID 12210290Read ↗

Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report.Semantic proximity Read ↗

Pharmacogenetics of Clinical Response to RisperioneSemantic proximity Read ↗

The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.Semantic proximity Read ↗

Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients.Semantic proximity Read ↗

[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].Semantic proximity Read ↗

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.Semantic proximity Read ↗

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.Semantic proximity Read ↗

A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.Semantic proximity Read ↗

Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.Semantic proximity Read ↗

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.Semantic proximity Read ↗

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.Semantic proximity Read ↗

Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.